CPH Chemie + Papier Holding AG (VTX:CPHN): Set To Experience A Decrease In Earnings?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Looking at CPH Chemie + Papier Holding AG's (VTX:CPHN) earnings update in December 2018, it seems that analyst forecasts are fairly bearish, as a 4.7% fall in profits is expected in the upcoming year compared with the past 5-year average growth rate of 84%. Currently with a trailing-twelve-month profit of CHF42m, the consensus growth rate suggests that earnings will drop to CHF40m by 2020. In this article, I've outline a few earnings growth rates to give you a sense of the market sentiment for CPH Chemie + Papier Holding in the longer term. For those interested in more of an analysis of the company, you can research its fundamentals here.

See our latest analysis for CPH Chemie + Papier Holding

Advertisement

Can we expect CPH Chemie + Papier Holding to keep growing?

The longer term expectations from the 3 analysts of CPHN is tilted towards the negative sentiment. Since forecasting becomes more difficult further into the future, broker analysts generally project out to around three years. To reduce the year-on-year volatility of analyst earnings forecast, I've inserted a line of best fit through the expected earnings figures to determine the annual growth rate from the slope of the line.

SWX:CPHN Past and Future Earnings, July 16th 2019
SWX:CPHN Past and Future Earnings, July 16th 2019

This results in an annual growth rate of -2.1% based on the most recent earnings level of CHF42m to the final forecast of CHF40m by 2022. EPS reaches CHF6.73 in the final year of forecast compared to the current CHF7.05 EPS today. The primary reason for earnings contraction is due to cost growth exceeding top-line growth of 2.5% in the next three years. With this high cost growth, margins is expected to contract from 7.9% to 6.9% by the end of 2022.

Next Steps:

Future outlook is only one aspect when you're building an investment case for a stock. For CPH Chemie + Papier Holding, there are three essential factors you should further research:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Valuation: What is CPH Chemie + Papier Holding worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether CPH Chemie + Papier Holding is currently mispriced by the market.
  3. Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of CPH Chemie + Papier Holding? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About SWX:CPHN

CPH Group

Develops, manufactures, and distributes chemical products and packaging solutions for pharmaceutical customers in Europe, Asia, and North and South America.

Excellent balance sheet, good value and pays a dividend.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2554.7% undervalued
108 users have followed this narrative
0 users have commented on this narrative
24 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4859.0% undervalued
213 users have followed this narrative
8 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43047.7% undervalued
20 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9953.6% undervalued
25 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

SI
MSFT logo
simplydunno on Microsoft ·

Microsoft's Capex Bill Comes Due Before the AI Revenue Does

Fair Value:US$512.123.7% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
NGXGROUP logo
Henrynuke03 on Nigerian Exchange Group ·

Future Growth Awaits NGXGROUP with New High-Profile Listings

Fair Value:₦221.1732.3% undervalued
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PR
PrashhD
AURIONPRO logo
PrashhD on Aurionpro Solutions ·

Aurionpro Solutions: Is the Market Mispricing One of India's Most Interesting Fintech Product Companies?

Fair Value:₹1k27.1% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28032.1% undervalued
211 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.0% undervalued
97 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6510.2% undervalued
74 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
RU
MSFT logo
ruslanchema on Microsoft ·

good thanks

0
|
0